BM 131074
Latest Information Update: 13 Apr 2007
Price :
$50 *
At a glance
- Originator Roche
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 13 Apr 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in Germany (unspecified route)
- 26 Feb 2001 Profile reviewed but no significant changes made
- 10 Jul 1998 No-Development-Reported for Type-2 diabetes mellitus in Germany (Unknown route)